Market Intelligence, Clinical Progress, and High-Purity Reagents for Tissue Regeneration, Ophthalmic, and Wound Healing Therapy Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for TMSB4X drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | TMSB4X Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified by MS. Suitable for actin-binding assays. |
View TMSB4X Products |
| Gene Delivery | TMSB4X Promise-ORF / Lentivirus Full-length ORF for stable cell lines to evaluate migration and wound healing. |
View TMSB4X Products |
| Benchmark Ab | Anti-TMSB4X Antibody Recombinant positive control for Western Blot, ELISA, and IHC. |
View TMSB4X Products |
| Validator | TMSB4X siRNA Set For knockdown verification in functional cell-based assays. |
View TMSB4X Products |
| Related Target A | ACTB (Beta-Actin) Primary intracellular binding partner; essential for G-actin sequestration assays. |
View ACTB Products |
| Related Target B | VEGFA Downstream angiogenic mediator; critical for evaluating synergistic tissue repair. |
View VEGFA Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Actin-binding affinity validation | High-purity recombinant TMSB4X with verified monomeric state and theoretical MW confirmation. |
| Ophthalmic / Wound healing formulation safety | Strictly endotoxin-controlled recombinant proteins (<1.0 EU/μg) to prevent inflammatory artifacts. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies available. |
| False Positives in Migration Assays | Sequence-specific siRNA pool included for target knockdown validation. |
Live TMSB4X R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for TMSB4X therapeutics is intensifying, with major players shifting focus from traditional systemic peptides to localized formulations, particularly in ophthalmology (dry eye syndrome) and dermal wound healing. As first-generation synthetic peptides (such as RGN-259) progress through late-stage clinical trials, the next wave of R&D is targeting optimized recombinant variants, gene therapy vectors for sustained localized expression, and combination therapies targeting synergistic angiogenic pathways.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Synthetic Peptide | RegeneRx Biopharmaceuticals, HLB Therapeutics | Dry Eye Syndrome, Neuroprotection | Actin Polymerization Inhibition Assay (Need high-purity ACTB and TMSB4X) |
| Gene Therapy / Lentivirus | Academic Institutes, Biotech Startups | Myocardial Infarction, Corneal Wound Healing | In vitro transduction validation (Need high-titer Lentivirus & siRNA validation) |
| Recombinant Protein | Biopharma Innovators | Dermal Wound Healing, Anti-fibrotic Therapy | Endotoxin-free protein for cell migration/scratch assays |